HER2-低乳腺癌:现在和未来
1Division of Hemato-oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Cancer research and treatment
|January 31, 2024
概括
新型抗体-药物联合体在低HER2水平的乳腺癌中显示出有效性,挑战了以前的治疗模式. 现在对HER2-低瘤生物学和预后的进一步研究至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 临床试验 临床试验
背景情况:
- 乳腺癌异质性是由激素受体和人体表皮生长因子受体2 (HER2) 表达定义的.
- 低HER2乳腺癌 (免疫组织化学1+或2+,无基因放大) 以前被认为不能用抗HER2药物治疗.
- 在历史上,Trastuzumab的疗效试验排除了HER2低的病例.
研究的目的:
- 审查目前关于低HER2乳腺癌的证据.
- 要突出新型抗体-药物结合物的对HER2-低瘤的影响.
- 确定 HER2 低乳腺癌生物学和预后的未来研究领域.
主要方法:
- 关于临床前和临床研究的综合文献综述.
- 对新型抗HER2疗法的最新临床试验数据的分析.
- 关于 HER2-低瘤特征的证据综合.
主要成果:
- 新兴的抗体-药物联合体,如trastuzumab-deruxtecan,在HER2-低乳腺癌中表现出显著的疗效.
- 这些发现挑战了对HER2-低瘤的传统观点,即瘤对向治疗没有反应.
- 低HER2乳腺癌是一种新发现的,可治疗的亚型.
结论:
- 新型抗HER2抗体-药物联合体为HER2-低乳腺癌提供了有前途的治疗途径.
- 低HER2瘤的生物学和预后意义需要进一步调查.
- 本综述强调了乳腺癌治疗和分类的不断变化的格局.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Vaccines
367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367
